Article
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2010
Adjei Araba A, Salavaggione Oreste E, Mandrekar Sumithra J, Dy Grace K, Ziegler Katie L Allen, Endo Chiaki, Molina Julian R, Schild Steven E, Adjei Alex A
Abstract excerpt
PURPOSE: To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed. EXPERIMENTAL DESIGN: Data from a phase II NSCLC trial evaluating the optimal schedule of gemcitabine and pemetrexed were used. All patients with available DNA were genotyped for polymorphisms in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
